Arsanis (NASDAQ:ASNS) posted its quarterly earnings results on Friday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.02), MarketWatch Earnings reports.
Arsanis stock traded down $0.06 during mid-day trading on Friday, hitting $1.37. The company’s stock had a trading volume of 857,225 shares, compared to its average volume of 198,372. The company has a debt-to-equity ratio of 0.20, a quick ratio of 5.54 and a current ratio of 5.54. The firm has a market cap of $19.75 million and a price-to-earnings ratio of -0.08. Arsanis has a twelve month low of $1.25 and a twelve month high of $28.69.
Several research analysts have issued reports on the stock. Piper Jaffray Companies decreased their price target on shares of Arsanis to $2.50 and set a “neutral” rating on the stock in a research report on Monday, August 13th. Zacks Investment Research lowered shares of Arsanis from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. Finally, ValuEngine upgraded shares of Arsanis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $14.88.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Read More: Leveraged Buyout (LBO)
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.